As depicted, the genome sequencing cost is decreasing while the production (TB) is increasing. It is expected that the cost of genome sequencing would ultimately drop to as low as $100 by 2025. As a result, it is highly possible that the use of genome sequencing will become more widely adopted and integrated into regular clinical practice, thereby bolstering the scope of companion diagnostic usage across the healthcare continuum for treatment preferences. As per BIS Research analysis, the global companion diagnostics market is projected to reach $7,536.7 million by 2030 from $1,764.7 million in 2019, at a CAGR of 12.45% during the forecast period of 2020-2030. This growth has been primarily attributed to the major drivers in this market, which comprise the growing incidence of cancer within the global population that has intensified the demand for better treatment assurance for all cancer types. Additionally, the growing demand for personalized medicine and the regulatory mand...